italian HIV AIDS vaccine English HIV AIDS vaccine
HIV AIDS TAT Vaccines logo image
 
  HOME
 
 

HIV e AIDS
    Cos’è l’AIDS
    Vie di trasmissione
    Primi sintomi
    Avere l’AIDS
    Si può curare l’AIDS?
   
 

LA NECESSITA’ DI AVERE UN VACCINO
    AIDS nel mondo
    AIDS in Africa
   
  TAT di HIV-1
  UN APPROCCIO VACCINALE INNOVATIVO
    Background scientifico e razionale
    La proteina Tat di HIV-1
    Studi pre-clinici
    Studi clinici
    Collaborazioni internazionali
 
  CANDIDATI VACCINALI TAT
 
    1a generazione: Tat
    2a generazione: Tat + Microparticelle
    2a generazione: Tat + Env
    Nuovi prodotti della ricerca
  PRODUZIONE DEL VACCINO
  PIANI DI SPERIMENTAZIONE CLINICA
  PROPRIETA’ INTELLETTUALI
  NOTIZIE
 
 
 
  PUBBLICAZIONI SCIENTIFICHE
In grassetto: ricercatori del Centro Nazionale AIDS
  1. Ensoli B., Fiorelli V., Ensoli F., Lazzarin A., Visintini R.,Narciso P.,Di Carlo A., Monini, P., Magnani M. and Garaci E. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. Research Letters AIDS 2008, 22:2207-2217. Click here to download .pdf

  2. Caputo A., Sparnacci K., Ensoli B., and Tondelli L. Functional polymeric nano/microparticles for surface adsorption and delivery of protein and DNA. Curr. Drug Delivery, in press.

  3. Ferrantelli F., Cafaro A., Macchia I., Maggiorella M.T. , Longo O. , Monini P. , Titti F. , Ensoli F., and Ensoli B. Clinical trials of HIV/AIDS vaccine candidates ? where are we and what is next? Expert Rev. on Vaccines, in press.

  4. Florese R.H., Wiseman R.W., Venzon D., Karl J.A., Demberg T., Larsen K., Flanary L., Kalyanaraman V.S., Pal R., Titti F., Patterson L.J., Heath M.J., O'Connor D.H., Cafaro A., Ensoli B., and Robert-Guroff M. Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV896P infection. Vaccine, in press.

  5. Borsetti A., Baroncelli S., Maggiorella M.T., Bellino S., Moretti S., Sernicola L., Belli R., Ridolfi B., Farcomeni S., Negri D.R.M., Cafaro A., Ensoli B., and Titti F. Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. Arch. Virol., 153:463-472, 2008. Click here to download .pdf

  6. Caputo A., Brocca-Cofano E., Castaldello A., Voltan R., Gavioli R., Srivastava I.K., Barnett S.W., Cafaro A., and Ensoli B. Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 ?V2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin. Vaccine, 26:1214-1227, 2008. Click here to download .pdf

  7. Ridolfi B., Genovese D., Argentini C., Maggiorella M.T., Sernicola L., Buttò S., Titti F., Borsetti A., and Ensoli B. Tat protein vaccination of cynomolgus macaques influences SHIV-89.6Pcy243 epitope variability. Virus Genes, 36:105-115, 2008. Click here to download .pdf

  8. Cafaro A., Macchia I., Maggiorella M.T., Titti F., and Ensoli B. Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS. Mol. Biotechnol., in press.

  9. Ensoli B., Nappi F., Ferrantelli F. and Buttò S. Meccanismo di infezione dei virus dell'immunodeficienza acquisita (HIV-1, HIV-2, SIV). Enciclopedia Medica Italiana (Third Update, II Edition), in press.

  10. Gudmunsdotter L., Bernasconi D., Hejdeman B., Sandstrom E., Alaeus A., Lidman K., Ensoli B., Wahren B., and Buttò S. Cross clade immune responses to gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles. Vaccine, in press.

  11. Sgarbanti M., Remoli A.L., Marsili G., Ridolfi B., Borsetti A., Perrotti E., Orsetti R., Ilari R., Sernicola R., Stellacci E., Ensoli B., Battistini A. IRF-1 is required for full NF-kb transcriptional activity at the HIV-1 LTR enhancer. J. Virol., 82:3632-3641, 2008. Click here to download .pdf

  12. Dehò L., Walwema R., Cappelletti A., Sukati H., Nsibandze D., Almaviva M., Buttò S., Ensoli B., Galli M., and Balotta C. Characterization of human immunodeficiency virus type 1 from antiretroviral drug-naïve population in Swaziland. AIDS Res. Hum. Retrovir. 24:323-325, 2008. Click here to download .pdf

  13. Gavioli R., Cellini S., Castaldello A., Voltan R., Gallerani E., Gagliardoni F., Fortini C., Brocca-Cofano E.., Triulzi C., Cafaro A., Srivastava I., Barnett S., Caputo A., and Ensoli B. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS. Vaccine 2008, 26:727-737. Click here to download .pdf

  14. Ensoli B. AIDS Vaccine Integrated project (AVIP): a Consortium funded by the FP-6 EU Program. In The Parliament Magazine November 26th 2007, Issue 257. Click here to download .pdf

  15. Bråve A., Hinkula J., Cafaro A., Eriksson L.E., Srivastava I.K., Magnani M., Ensoli B., Barnett S.W., Wahren B., Rollman E. Candidate HIV-1 gp140deltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. Vaccine 2007, 25:6882-6890. Click here to download .pdf

  16. Demberg T, Florese RH, Heath MJ, Larsen K, Kalisz I, Kalyanaraman VS, Lee EM, Pal R, Venzon D, Grant R, Patterson LJ, Korioth-Schmitz B, Buzby A, Dombagoda D, Montefiori DC, Letvin NL, Cafaro A, S B, Robert-Guroff M. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2007; 81:3414-3427. Click here to download .pdf

  17. Maggiorella M.T., Sernicola L., Crostarosa F., Belli R., Pavone-Cossut M.R., Macchia I., Tenner-Racz K., Racz P., Ensoli B., and Titti F. Multiprotein Genetic Vaccine in the SIV-Macaca animal model: a promising approach to generate sterilising immunity to HIV infection. J. Med. Primatol. 2007, 36:180-194. Click here to download .pdf

  18. Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell JL, Derdeyn CA. Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol 2007; 81:1350-1359.

  19. Titti F., Cafaro A., Ferrantelli F., Tripiciano A., Moretti S., Caputo A., Gavioli R.., Ensoli F., Robert-Guroff M., Barnett S., and Ensoli B. Problems and emerging approaches in HIV/AIDS vaccine development. Exp. Opin. Emerg. Drugs 2007, 12:23-48. Click here to download .pdf

  20. Voltan R, Castaldello A, Brocca-Cofano E, Altavilla G, Caputo A, Laus M, Sparnacci K, Ensoli B, Spaccasassi S, Ballestri M, Tondelli L. Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes. Pharm Res 2007; 24:1870-1882. Click here to download .pdf

  21. Ataman-Onal Y, Munier S, Ganee A, Terrat C, Durand PY, Battail N, Martinon F, Le Grand R, Charles MH, Delair T, Verrier B. Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. J Control Release 2006; 112:175-185.

  22. Borsutzky S., Ebensen T., Link C., Daniel Becker P., Fiorelli V., Cafaro A., Ensoli B., and Guzmán C.A. Efficient systemic and mucosal responses against the HIV-1 Tat protein by Prime/Boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine 2006, 24:2049-2056. Click here to download .pdf

  23. Bozac A., Berto E., Vasquez F., Grandi P., Caputo A., Manservigi R., Ensoli B., and Marconi P. Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses. Vaccine 2006, 24:7148-7158. Click here to download .pdf

  24. Castaldello A., Brocca-Cofano E., Voltan R., Triulzi C., Altavilla G., Laus M., Sparnacci K., Balestri M., Tondelli L., Fortini C., Gavioli R.., Ensoli B., and Caputo A. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. Vaccine 2006, 24:5655-5669. Click here to download .pdf

  25. Chiarantini L, Cerasi A, Millo E, Sparnacci K,Laus M, Riccio M, Santi S, Ballestri M, Spaccasassi S, Tondelli L. Enhanced antisense effect of modified PNAs delivered through functional PMMA microspheres. I. J. Pharm. 324 2006 83-91. Click here to download .pdf

  26. Ensoli B, Fiorelli V, Ensoli F, Cafaro A, Titti F, Buttò S, Monini P, Magnani M, Caputo A, Garaci E. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS 2006; 20:2245-2261. Click here to download .pdf

  27. Ferrantelli F, Buttò S, Cafaro A, Wahren B, Ensoli B. Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience. Springer Semin Immun (2006) 28:289-301 Click here to download .pdf

  28. Garrafa E., Alessandri G., Benetti A., Turetta D., Corradi A., Cantoni A.M., Cervi E., Bonardelli S., Parati E., Giulini S.M., Ensoli B., and Caruso A. Isolation and characterization of lymphatic microvascular endothelial cells from human tonsils J. Cell. Physiol. 2006, 207:107-113. Click here to download .pdf

  29. Humbert M,Dietrich U. The role of neutralizing antibodies in HIV infection. AIDS Rev 2006; 8:51-59.

  30. Remoli AL, Marsili G, Perrotti E, Gallerani E, Ilari R, Nappi F, Cafaro A, Ensoli B, Gavioli R, Battistini A. Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. Biochem J 2006; 396:371-380. Click here to download .pdf

  31. Sagar M, Wu X, Lee S, Overbaugh J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 2006; 80:9586-9598.

  32. Toschi E., Bacigalupo I., Strippoli R., Cereseto A., Falchi M., Chiozzini C., Nappi F., Sgadari C., Barillari G., Mainiero F., and Ensoli B. HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathway. Mol. Biol. Cell 2006, 17:1985-1994. Click here to download .pdf

  33. Alfsen A, Yu H, Magerus-Chatinet A, Schmitt A, Bomsel M. HIV-1-infected blood mononuclear cells form an integrin- and agrin-dependent viral synapse to induce efficient HIV-1 transcytosis across epithelial cell monolayer. Mol Biol Cell 2005; 16:4267-4279.

  34. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B, Overbaugh J. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 2005; 79:6528-6531.

  35. Ensoli B. Introduction: rational vaccine strategies against AIDS. Microbes Infect. 2005, 7:1385. Click here to download .pdf

  36. Ensoli B. AIDS Vaccine Integrated Project (AVIP). BIOForum Europe 2005, Volume 9: 38-40.Click here to download .pdf

  37. Ensoli B. Rational vaccine strategies against AIDS: background and rationale. Microbes Infect. 2005, 7:1445-1452. Click here to download .pdf

  38. Ensoli B. Criteria for selection of HIV vaccine candidates-general principles. Microbes Infect. 2005, 7:1433-1435. Click here to download .pdf

  39. Ensoli B., Cafaro A., Caputo A., Fiorelli V., Ensoli F., Gavioli R.., Ferrantelli F., Cara A., Titti F., and Magnani M. Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env. Microbes Infect. 2005, 7:1392-1399. Click here to download .pdf

  40. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF and the rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-665.

  41. Istituto Superiore di Sanità. WO2005/090391 (2005)

  42. Kasturi SP, Sachaphibulkij K, Roy K. Covalent conjugation of polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA vaccines. Biomaterials 2005; 26:6375-6385.

  43. Marchio S, Alfano M, Primo L, Gramaglia D, Butini L, Gennero L, De Vivo E, Arap W, Giacca M, Pasqualini R, Bussolino F. Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein. Blood 2005; 105:2802-2811.

  44. Pancera M, Lebowitz J, Schon A, Zhu P, Freire E, Kwong PD, Roux KH, Sodroski J, Wyatt R. Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis. J Virol 2005; 79:9954-9969.

  45. Rezza G, Fiorelli V, Dorrucci M, Ciccozzi M, Tripiciano A, Scoglio A, Collacchi B, Ruiz-Alvarez M, Giannetto C, Caputo A, Tomasoni L, Castelli F, Sciandra M, Sinicco A, Ensoli F, Buttò S, Ensoli B. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis 2005; 191:1321-1324. Click here to download .pdf

  46. Sparnacci K., Laus M., Tondelli L., Bernardi C., Magnani L., Corticelli F., Marchisio M., Ensoli B., Castaldello A., and Caputo A. Core-shell microspheres by dispersion polymerization as promising delivery systems for proteins. J. Biomater. Sci. Polymer. Edn 2005, 16:1557-1574. Click here to download .pdf

  47. Zhao J., Voltan R., Peng B., Davis-Warren A., Kalyanaraman V.S., Alvord W.G., Aldrich K., Bernasconi D., Buttò S., Cafaro A., Ensoli B., and Robert-Guroff M. Enhanced cellular immunity to SIV Gag following co-administration of Adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. Virology 2005, 342:1-12. Click here to download .pdf

  48. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 2004; 5:233-236. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5:233-236.

  49. Caputo A., Brocca-Cofano E., Castaldello A., Altavilla G., De Michele R. , Marchisio M., Gavioli R.., Rolen U., Chiarantini L., Cerasi A., Dominici S., Magnani M., Cafaro A., Sparnacci K., Laus M., Tondelli L., and Ensoli B. Novel biocompatible anionic polymeric microspheres for the delivery of the HIV 1 Tat protein for vaccine application. Vaccine 2004, 22:2910-24.Click here to download .pdf

  50. Caputo A., Gavioli R.. and Ensoli B. Recent advances in the development of HIV-1 Tat-based vaccines. Curr. HIV Res. 2004, 2:357-376. Click here to download .pdf

  51. Cara A., Maggiorella M.T., Bona R., Sernicola L., Baroncelli S., Negri D.R.M., Leone P., Fagrouch Z., Heeney J., Titti F., Cafaro A., and Ensoli B. Circular viral DNA detection and junction sequence analysis from PBMC of SHIV-infected cynomolgus monkeys with undetectable virus plasma RNA. Virology 2004, 324:531-9.Click here to download .pdf

  52. Ferrantelli F., Cafaro A., and Ensoli B. Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. Curr. Opin. Biotech. 2004, 15:543-56. Click here to download .pdf

  53. Franzese O., Comandini A., Adamo R., Sgadari C., Ensoli B., Bonmassar E. HIV-Tat down-regulates telomerase activity in the nucleus of human CD4+ T cells. Cell Death Differ. 2004, 11:782-784. Click here to download .pdf

  54. Gavioli R., Gallerani E, Fortini C, Fabris M, Bottoni A, Canella A, Bonaccorsi A, Marastoni M, Micheletti F, Cafaro A, Rimessi P, Caputo A, Ensoli B. HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J Immunol 2004; 173:3838-3843. Click here to download .pdf

  55. Jones NA, Field T, Davalos M, Hart S. Greater right frontal EEG asymmetry and nonemphathic behavior are observed in children prenatally exposed to cocaine. Int J Neurosci 2004; 114:459-480.

  56. Maggiorella MT, Baroncelli S, Michelini Z, Fanales-Belasio E, Moretti S, Sernicola L, Cara A, Negri DR, Buttò S, Fiorelli V, Tripiciano A, Scoglio A, Caputo A, Borsetti A, Ridolfi B, Bona R, ten Haaft P, Macchia I, Leone P, Pavone-Cossut MR, Nappi F, Ciccozzi M, Heeney J, Titti F, Cafaro A, Ensoli B. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine 2004; 22:3258-3269. Click here to download .pdf

  57. Monini P., Sgadari C., Toschi E., Barillari G., and Ensoli B. Antitumor effects of antiretroviral activity. Nat. Cancer Rev. 2004, 4:861-875.Click here to download .pdf

  58. Mooij P., Nieuwenhuis I.G., Knoop C.J., Doms R.W., Bogers W.M.J.M., Ten Haaft P.J.F., Niphuis H., Koornstra W., Bieler K., Koestler J., Morein B., Cafaro A., Ensoli B., Wagner R., and Heeney J.L. Qualitative T-Helper Responses to Multiple Viral Antigens Correlate with Vaccine-Induced Immunity to Simian/Human Immunodeficiency Virus Infection. J. Virol. 2004, 78:3333-3342.Click here to download .pdf

  59. Negri D.R.M., Buffa V., Leone P., Bona R., Borghi M., Carlini F., De Angelis F., Indraccolo S., Ensoli B., Cara A. Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. J. Immunol. Methods 2004, 291:153-163. Click here to download .pdf

  60. O'Hagan DT,Rappuoli R. Novel approaches to vaccine delivery. Pharm Res 2004; 21:1519-1530.

  61. Singh M, Kazzaz J, Chesko J, Soenawan E, Ugozzoli M, Giuliani M, Pizza M, Rappouli R, O'Hagan DT. Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J Pharm Sci 2004; 93:273-282.

  62. Singh M, Chesko J, Kazzaz J, Ugozzoli M, Kan E, Srivastava I, O'Hagan DT. Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not. Pharm Res 2004; 21:2148-2152.

  63. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 2004; 4:199-210.

  64. Borsutzky S., Fiorelli V., Ebensen T., Tripiciano A., Rharbaoui F., Scoglio A., Link C., Nappi F., Morr M., Buttò S., Cafaro A., Mühlradt P.F., Ensoli B., and Guzman CA. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur. J. Immunol. 2003, 33:1548-1556. Click here to download .pdf

  65. Buttò S, Fiorelli V, Tripiciano A, Ruiz-Alvarez MJ, Scoglio A, Ensoli F, Ciccozzi M, Collacchi B, Sabbatucci M, Cafaro A, Guzmán CA, Borsetti A, Caputo A, Vardas E, Colvin M, Lukwiya M, Rezza G, Ensoli B and the Tat Multicentric Study Group. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans. J Infect Dis 2003; 188:1171-1180.Click here to download .pdf

  66. Cao J, McNevin J, Malhotra U, McElrath MJ. Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection. J Immunol 2003; 171:3837-3846.

  67. Caputo A, Gavioli R., Altavilla G, Brocca-Cofano E, Boarini C, Betti M, Castaldello A, Lorenzini F, Micheletti F, Cafaro A, Sparnacci K, Laus M, Tondelli L, Ensoli B. Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat. Vaccine 2003; 21:1103-1111.Click here to download .pdf

  68. Cosma A, Nagaraj R, Buhler S, Hinkula J, Busch DH, Sutter G, Goebel FD, Erfle V. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 2003; 22:21-29.

  69. Dominici S., Laguardia M.E., Serafini G., Chiarantini L., Fortini C., Tripiciano A., Brocca-Cofano E., Scoglio A., Caputo A., Fiorelli V., Gavioli R.., Cafaro A., Ensoli B., and Magnani M. Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL. Vaccine 2003, 21:2082-2090.Click here to download .pdf

  70. Istituto Superiore di Sanità. WO2003/009867 (2003)

  71. Luo Y, O'Hagan D, Zhou H, Singh M, Ulmer J, Reisfeld RA, James Primus F, Xiang R. Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEA-transgenic mice. Vaccine 2003; 21:1938-1947.

  72. Marinaro M., Riccomi A., Rappuoli R., Pizza M., Fiorelli V., Tripiciano A., Cafaro A., Ensoli B., and De Magistris M.T. Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA. Vaccine 2003, 21(25-26)-3503-4094. Click here to download .pdf

  73. O'Hagan DT,Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines 2003; 2:269-283.

  74. Richardson MW, Mirchandani J, Duong J, Grimaldo S, Kocieda V, Hendel H, Khalili K, Zagury JF, Rappaport J. Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. Biomed Pharmacother 2003; 57:4-14.

  75. Sgadari C., Monini P., Barillari G. and Ensoli B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol. 2003, 4:537-547.Click here to download .pdf

  76. Almond N., Anzala O., Bektimirov T., Berman P., Birx D., Carvalheiro J., Chongprasert S., Cichutek K., Darbyshire J., Duarte C., Ensoli B., Fenyo E.M., Girard M., Goldenthal K., Golding H., Holmes H., Johnston M., Mallet L., Mawle A., Mugerwa R., Pitisuttithum P., Rees H., Robertson J., Rowland-Jones S., Sang G., Schild G., Shao Y., Sheets R., Takemori T., Tramont E., Vandepapeliere P., van der Groen G., Weiner D., and Widdus R. Scientific considerations for the regulation and clinical evaluation of HIV/AIDS preventive vaccines. (Collective views of an international group of experts, Report from a WHO-UNAIDS Consultation, Geneva, Switzerland, March 13-15, 2001); AIDS 2002, 16:W15-W25.Click here to download .pdf

  77. Barillari G., and Ensoli B. Angiogenic Effects of Extracellular Human Immunodeficiency virus type 1 Tat Protein and its role in the pathogenesis of AIDS-associated Kaposi's Sarcoma. Clin. Microbiol. Rev 2002, 15:310-32. Click here to download .pdf

  78. Caputo A., Betti M., Altavilla G., Bonaccorsi A., Boarini C., Marchisio M., Buttò S., Sparnacci K., Laus M., Tondelli L., and Ensoli B. Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application. Vaccine 2002, 20:2303-2317.Click here to download .pdf

  79. Ensoli B, Cafaro A. Mini Review HIV-1 Tat Vaccines. Virus Research 82 (2002) 91-101.Click here to download .pdf

  80. Fanales-Belasio E, Moretti S, Nappi F, Barillari G, Micheletti F, Cafaro A, Ensoli B. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol 2002; 168:197-206. Click here to download .pdf

  81. Fanales-Belasio E, et Al. HIV-1 Tat-based Vaccines; from basic Science to Clinical trials. DNA and Cell Biology Vol. 21, Number 9, 2002 . Click here to download .pdf

  82. Hel Z, Johnson JM, Tryniszewska E, Tsai WP, Harrod R, Fullen J, Tartaglia J, Franchini G. A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine. Vaccine 2002; 20:3171-3186.

  83. Novitsky V, Cao H, Rybak N, Gilbert P, McLane MF, Gaolekwe S, Peter T, Thior I, Ndung'u T, Marlink R, Lee TH, Essex M. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol 2002; 76:10155-10168.

  84. O'Connor DH, Allen TM, Vogel TU, Jing P, DeSouza IP, Dodds E, Dunphy EJ, Melsaether C, Mothé B, Yamamoto H, Horton H, Wilson N, Hughes AL, Watkins DI. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med 2002; 8:493-499.

  85. O'Hagan DT,Lavelle E. Novel adjuvants and delivery systems for HIV vaccines. AIDS 2002; 16 Suppl 4:S115-S124.

  86. Rharbaoui F., Drabner B., Borsutzky S., Winckler U., Morr M., Ensoli B., Mühlradt P.F., and Guzman C.A. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur. J. Immunol. 2002, 32:2857-2865.Click here to download .pdf

  87. Sgadari C., Barillari G., Toschi E., Carlei D., Bacigalupo I., Baccarini S., Palladino C., Leone P., Bugarini R., Malavasi L., Cafaro A., Falchi M., Valdembri D., Rezza G., Bussolino F., Monini P., and Ensoli B. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi's sarcoma. Nat. Med. 2002, 8:225-232.Click here to download .pdf

  88. Sgarbanti M., Borsetti A., Moscufo N. , Bellocchi M.C., Ridolfi B., Nappi F., Marsili G., Marziali G., Coccia E.M., Ensoli B., and Battistini A. Modulation of HIV-1 Replication by Interferon Regulatory Factors. J. Exp. Med. 2002, 195:1359-1370.Click here to download .pdf

  89. Stittelaar KJ, Gruters RA, Schutten M, , van Baalen CA, van Amerongen G, Cranage M, Liljeström P, Sutter G, Osterhaus AD. Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine 2002; 20:2921-2927.

  90. Verrier B, Le GR, Ataman-Onal Y, Terrat C, Guillon C, Durand PY, Hurtrel B, Aubertin AM, Sutter G, Erfle V, Girard M. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08. DNA Cell Biol 2002; 21:653-658.

  91. Accorsi S., Fabiani M., Lukwija M., Onek P.A., Di Mattei P., Declich S. for the Italian-Ugandan AIDS Cooperation Program (Greco D., Dente M.G., Tancredi P., Ranghiasci A., Corti P., Corrado B., Onyut A., Ouma J., Hasman A., Biryahwabo B., Rosolen T., Ensoli B., Buttò S., Clerici M., Zagliani A., Rizzardini G., Milazzo F., Piconi S., Ferrante P., Saresella M., Aloi A., Cosulich A). The increasing burden of infectious diseases on hospital services at St. Mary's Hospital Lacor, Gulu, Uganda. Am. J. Trop. Med. Hyg. 2001, 64:154-158. Click here to download .pdf

  92. Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Philips MN, Habeeb K, Khatri A, Brander C, Robbins GK, Mazzara GP, Goulder PJ, Walker BD, HIV Controller Study Collaboration. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci U S A 2001; 98:1781-1786.

  93. Betti M., Voltan R., Marchisio M., Mantovani I., Boarini C., Nappi F., Ensoli B., and Caputo A. Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application. Vaccine 2001, 19:3408-3419. Click here to download .pdf

  94. Bussolino F., Mitola S., Serini G., Barillari G., and Ensoli B. Interactions between endothelial cells and HIV-1. Int. J. Biochem. Cell Biol. 2001, 33:371-390.Click here to download .pdf

  95. Cafaro A, Titti F, Fracasso C, Maggiorella MT, Baroncelli S, Caputo A, Goletti D, Borsetti A, Pace M, Fanales-Belasio E, Ridolfi B, Negri DR, Sernicola L, Belli R, Corrias F, Macchia I, Leone P, Michelini Z, ten Haaft P, Buttò S, Verani P, Ensoli B. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 2001; 19:2862-2877.Click here to download .pdf

  96. De Maria A., Biassoni R., Fogli M., Rizzi M., Cantoni C., Costa P., Conte R., Mavilio D., Ensoli B., Cafaro A., Moretta A., Moretta L. Identification, molecular cloning and functional characterization of NKp46 and NKp30 natural cytotoxicity receptors in Macaca Fascicularis NK cells. Eur. J. Immunol. 2001, 31:3546-3556.Click here to download .pdf

  97. Ensoli B, Sgadari C, Barillari G, Sirianni MC, Stürzl M, Monini P. Biology of Kaposi's sarcoma. Eur J Cancer 2001; 37:1251-1269. Click here to download .pdf

  98. Ensoli B., Stürzl M., and Monini P. Reactivation and role of HHV-8 in Kaposi'sarcoma initiation. Adv. Cancer Res. 2001, 81:161-200. Click here to download.pdf

  99. Ensoli B., and Cafaro A. Novel strategies toward the development of an effective vaccine to prevent Human Immunodeficiency Virus infection or Acquired Immunodeficiency Virus. In: AIDS Clinical Review 2000/2001, Volberding and Jacobson Eds., pp. 23-61. Click here to download.pdf

  100. Guenzi E., Töpolt K., Cornali E., Lubeseder-Martellato C., Zietz C., Kremmer E., Nappi F., Schwemmle M., Hohenadl C., Jörg A., Matzen K., Barillari G., Tschachler E., Monini P., Ensoli B., and Stürzl M. The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. EMBO J. 2001, 20:5568-5577.Click here to download .pdf

  101. Kolchinsky P, Kiprilov E, Bartley P, Rubinstein R, Sodroski J. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J Virol 2001; 75:3435-3443.

  102. Laus M., Sparnacci K., Ensoli B., Buttò S., Caputo A., Mantovani I., Zuccheri G., Samorì B., and Tondelli L. Complex associates of plasmid DNA and a novel class of block Copolymers with PEG and cationic segments as new vectors for gene delivery. J. Biomater. Sci. Polym. Ed. 2001, 12:209-228. Click here to download.pdf

  103. Novitsky V, Rybak N, McLane MF, Gilbert P, Chigwedere P, Klein I, Gaolekwe S, Chang SY, Peter T, Thior I, Ndung'u T, Vannberg F, Foley BT, Marlink R, Lee TH, Essex M. Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. J Virol 2001; 75:9210-9228.

  104. O'Hagan DT. Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord 2001; 1:273-286.

  105. Schatz O., Monini P., Bugarini R., Neipel F., Schulz T.F., Andreoni M., Erb P., Eggers M., Haas J., Buttò S., Lukwiya M., Bogner J.R, Yaguboglu S., Sheldon J., Sarmati L., Goebel F. D., Hintermaier R., Enders G., Regamey N., Wernli M., Stürzl M., Rezza G., and Ensoli B. Kaposi's sarcoma-associated herpesvirus serology in Europe and Uganda: multicentre study with multiple and novel assays. J. Med. Virol. 2001, 65:123-132.Click here to download .pdf

  106. ten Haaft P., Almond N., Biberfeld G., Cafaro A. Cranage M.,, Ensoli B., Hunsmann G., Polyanskaya N., Stahl-Henning C. Thortensson R, Titti F. Heeney J. Comparison of early plasma RNA loands in different macaque species and the impact of different routes of exposure on SIV/SHIV infection. J.Med Primatol 2001: 30: 207-214. Click here to download .pdf

  107. Toschi E., Barillari G., Sgadari C., Bacigalupo I., Cereseto A., Carlei D., Palladino C., Zietz C., Leone P., Stürzl M., Buttò S., Cafaro A., Monini P., and Ensoli B. Activation of Matrix-Metalloproteinase-2 and Membrane-Type-1-Matrix-Metalloproteinase in Endothelial Cells and Induction of Vascular Permeability in vivo by the Human Immunodeficiency Virus-1 Tat protein and Basic Fibroblast Growth Factor. Mol. Biol. Cell 2001, 12:2934-2946. Click here to download .pdf

  108. Allen TM, O'Connor DH, Jing P, Dzuris JL, Mothé BR, Vogel TU, Dunphy E, Liebl ME, Emerson C, Wilson N, Kunstman KJ, Wang X, Allison DB, Hughes AL, Desrosiers RC, Altman JD, Wolinsky SM, Sette A, Watkins DI. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000; 407:386-390.

  109. Annunziato F., Galli G., Nappi F., Cosmi L., Manetti R., Maggi E., Ensoli B., and Romagnani S. Limited expression of R5-tropic HIV-1 in CCR-5 positive type 1-polarized T cells explained by their ability to reproduce RANTES, MIP-1beta and MIP-1beta. Blood 2000, 95:1167-1174. Click here to download .pdf

  110. Ayyavoo V, Kudchodkar S, Ramanathan MP, Le P, Muthumani K, Megalai NM, Dentchev T, Santiago-Barrios L, Mrinalini C, Weiner DB. Immunogenicity of a novel DNA vaccine cassette expressing multiple human immunodeficiency virus (HIV-1) accessory genes. AIDS 2000; 14:1-9.

  111. Borsetti A., Parolin C., Ridolfi B., Sernicola L., Geraci A., Ensoli B., and Titti F. CD4-independent infection of two CD4-/CCR5-/CXCR4+ pre-T-cell lines by human and simian immunodeficiency viruses. J. Virol. 2000, 74:6689-6894.Click here to download .pdf

  112. Cafaro A, Caputo A, Maggiorella MT, Baroncelli S, Fracasso C, Pace M, Borsetti A, Sernicola L, Negri DR, Ten Haaft P, Betti M, Michelini Z, Macchia I, Fanales-Belasio E, Belli R, Corrias F, Buttò S, Verani P, Titti F, Ensoli B. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. J Med Primatol 2000; 29:193-208.Click here to download .pdf

  113. Clerici M., Buttò S., Lukwiya M., Saresella M., Declich S., Trabattoni D., Pastori C., Piconi S., Fracasso C., Fabiani M., Ferrante P., Rizzardini G., and Lopalco L. for the Italian-Ugandan AIDS Project (Accorsi S., Amet O.A., Arienti D., Awil P.O., Barassi C., Benon B., Biasin M., Cogliati M., Colombo F., Corti P., Cristofaro A., Ensoli B., Fossati S., Fusi M.L., Greco D., Jacob O., Milazzo F., Ranghiasci A., Rosolen T., Villa M.L., Tancredi P., Zagliani A.). Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. AIDS 2000, 14:2083-2092.Click here to download .pdf

  114. Demirhan I, Chandra A, Mueller F, Mueller H, Biberfeld P, Hasselmayer O, Chandra P. Antibody spectrum against the viral transactivator protein in patients with human immunodeficiency virus type 1 infection and Kaposi's sarcoma. J Hum Virol 2000; 3:137-143.

  115. Kazzaz J, Neidleman J, Singh M, Ott G, O'Hagan DT. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J Control Release 2000; 67:347-356.

  116. van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res 2000; 17:1159-1167.

  117. Barillari G., Sgadari C., Palladino C., Gendelman R., Caputo A., Bohan Morris C., Nair B.C., Markham P., Nel A., Stürzl M., and Ensoli B. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and alfavbeta3 integrin. J. Immunol. 1999, 163:1929-1935.Click here to download .pdf

  118. Barillari G., Sgadari C., Fiorelli V., Samaniego F., Colombini S., Manzari V., Modesti A., Nair B.C., Cafaro A., Stürzl M., and Ensoli B. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alfa5beta1 and alfavbeta3 integrins by mobilizing sequestered basic fibroblast growth factor. Blood 1999, 94:663-672.Click here to download .pdf

  119. Cafaro A, Caputo A, Fracasso C, Maggiorella MT, Goletti D, Baroncelli S, Pace M, Sernicola L, Koanga-Mogtomo ML, Betti M, Borsetti A, Belli R, Akerblom L, Corrias F, Buttò S, Heeney J, Verani P, Titti F, Ensoli B. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 1999; 5:643-650.Click here to download .pdf

  120. Caselli E, Betti M, Grossi MP, Balboni PG, Rossi C, Boarini C, Cafaro A, Barbanti-Brodano G, Ensoli B, Caputo A. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat. J Immunol 1999; 162:5631-5638.Click here to download .pdf

  121. Fiorelli V., Barillari G., Toschi E., Sgadari C., Monini P., Stürzl M., and Ensoli B. IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis. J. Immunol. 1999, 162:1165-1170.Click here to download .pdf

  122. Istituto Superiore di Sanità. WO1999/27958 (1999)

  123. Monini P., Colombini S., Stürzl M., Goletti D., Cafaro A., Sgadari C., Buttò S., Franco M., Leone P., Fais S., Leone P., Melucci-Vigo G., Chiozzini C., Carlini F., Ascherl G., Cornali E., Ziezt C., Ramazzotti E., Ensoli F., Andreoni M., Pezzotti P., Rezza G., Yarchoan R., Gallo R.C., and Ensoli B. Reactivation and Persistence of Human Herpesvirus-8 Infection in B Cells and Monocytes by Th-1 Cytokines Increased in Kaposi's Sarcoma. Blood 1999, 93:4044-4058.Click here to download .pdf

  124. Osterhaus AD, van Baalen CA, Gruters RA, Schutten M, Siebelink CH, Hulskotte EG, Tijhaar EJ, Randall RE, van Amerongen G, Fleuchaus A, Erfle V, Sutter G. Vaccination with Rev and Tat against AIDS. Vaccine 1999; 17:2713-2714.

  125. Staprans SI, Dailey PJ, Rosenthal A, Horton C, Grant RM, Lerche N, Feinberg MB. Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. J Virol 1999; 73:4829-4839.

  126. Fiorelli V., Gendelman R., Sirianni M.C., Chang H.K., Colombini S., Markham P.D., Monini P., Sonnabend J., Pintus A., Gallo R.C., and Ensoli B. Gamma-interferon produced by CD8+ T cells infiltrating Kaposi's sarcoma induces spindle cells with angiogenic phenotype and synergy with Human Immunodeficiency Virus-1 Tat protein: an immune response to Human Herpes Virus-8 infection? Blood 1998, 91:956-967. Click here to download .pdf

  127. Kelly G.D., Ensoli B., Gunthel C. J., and Offermann M.K. Purified Tat induces inflammatory response genes in Kaposi's sarcoma cells. AIDS 1998, 12:1753-1761.Click here to download .pdf

  128. Rizzardini G., Trabattoni D., Saresella M., Piconi S., Lukwiya M., Declich S., Fabiani M., Ferrante P., Clerici M. for the Italian-Ugandan AIDS cooperation program. (Buttò S, Zanchetta N., Blé C., Zagliani A., Biasin M., Milazzo F., Greco D., Ensoli B., and Corti P.). Immune activation in HIV-infected African individuals. AIDS 1998, 12:2387-2396.Click here to download .pdf

  129. ten Haaft P, Verstrepen B, Uberla K, Rosenwirth B, Heeney J. A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J Virol 1998; 72:10281-10285.

  130. Tondelli l, Ricca A,Laus M,Lelli M,Citro G. HIghly efficient cellular updatke of c-myb antisense oligonucleotides through specifically designed polymeric nanospheres. NAR 1998 Vol.26,No. 23, 5425-5431.Click here to download .pdf

  131. van Baalen CA, Schutten M, Huisman RC, Boers PH, Gruters RA, Osterhaus AD. Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro. J Virol 1998; 72:6851-6857.

  132. Zagury JF, Sill A, Blattner W, Lachgar A, Le Buanec H, Richardson M, Rappaport J, Hendel H, Bizzini B, Gringeri A, Carcagno M, Criscuolo M, Burny A, Gallo RC, Zagury D. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol 1998; 1:282-292.

  133. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med 1997; 3:42-47.

  134. Chang H.C., Samaniego F., Nair B.C., Buonaguro L., and Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 1997, 11:1421-1431.Click here to download .pdf

  135. Lifson JD, Nowak MA, Goldstein S, Rossio JL, Kinter A, Vasquez G, Wiltrout TA, Brown C, Schneider D, Wahl L, Lloyd AL, Williams J, Elkins WR, Fauci AS, Hirsch VM. The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol 1997; 71:9508-9514.

  136. Watson A, Ranchalis J, Travis B, McClure J, Sutton W, Johnson PR, Hu SL, Haigwood NL. Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol 1997; 71:284-290.

  137. Lisziewicz J., Daisy Sun , Gallo RC, Ensoli B., Lori F., Efficacy of antitat Gene Therapy in the Presence of High Multiplicity Infection and Inflammatory Cytokines. Human Gene Therapy, 1996 7: 2209-2216 Click here to download.pdf

  138. Goldstein G. HIV-1 Tat protein as a potential AIDS vaccine. Nat Med 1996; 2:960-964.

  139. Brother M.B., Chang H.K., Lisziewicz J., Su D., Murty L.C., and Ensoli B Lisziewicz J., Sun Sun , gallo RC, Ensoli B. Block of Tat-mediated transactivation of tumor necrosis factor ß gene expression by polymeric-TAR decoys. Virology 1996, 222:252-256. Click here to download.pdf

  140. Mellors JW, Rinaldo CR, Jr., Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-1170.

  141. Albini A., Barillari G., Benelli R., Gallo R.C., and Ensoli B. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc. Natl. Acad. Sci. USA 1995, 92: 4838-4842.Click here to download .pdf

  142. Chang H.C., Gallo R.,Ensoli B. Regulation of cellular gene expression and function by the Human Immunodeficiency Virus Type 1 Tat Protein. J. Biomed Sci, 1995;2:189-202.Click here to download .pdf

  143. Fiorelli V., Gendelman R., Samaniego F., Markham P.D., and Ensoli B. Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells. J. Clin. Invest. 1995, 95: 1723-1734.Click here to download .pdf

  144. Lisziewicz J., Sun D., Trapnell B., Thomson M., Chang H.K., Ensoli B., and Peng B. An autoregulated dual-function antitat gene for human immunodeficiency virus type 1 gene therapy. J. Virol. 1995, 69: 206-212.Click here to download .pdf

  145. Re MC, Furlini G, Vignoli M, Ramazzotti E, Roderigo G, De Rosa V, Zauli G, Lolli S, Capitani S, La Placa M. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:408-416.

  146. Vandendriessche T., Chuah M.K.L., Chiang L., Chang H.K., Ensoli B., and Morgan R.A. Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes. J. Virol. 1995, 69: 4045-4052.Click here to download .pdf

  147. Buonaguro L., Buonaguro F.M., Giraldo G., and Ensoli B. The human immunodeficiency virus type 1 Tat protein transactivates tumor necrosis factor beta gene expression through a TAR-like structure. J. Virol. 1994, 68: 2677-2682.Click here to download .pdf

  148. Chang H.K., Gendelman R., Lisziewicz J., Gallo R.C., and Ensoli B. Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: A strategy for control of HIV-1. Gene Therapy 1994, 1: 208-216.Click here to download .pdf

  149. Chuah M.K.L., Vandendriessche T., Chang H.K., Ensoli B., and Morgan R.A. Inhibition of Human Immunodeficiency Virus Type-1 by retroviral vectors expressing antisense-TAR. Hum. Gene Ther. 1994, 5: 1467-1475. Click here to download .pdf

  150. Ensoli B, Gendelman R, Markham P, Fiorelli V, Colombini S, Raffeld M, Cafaro A, Chang HK, Brady JN, Gallo RC. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994; 371:674680. Click here to download .pdf

  151. Ensoli B., Markham P., Kao V., Barillari G., Fiorelli V., Gendelman R., Raffeld M., Zon G., and Gallo R.C. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. J. Clin. Invest. 1994, 94: 1736-1746. Click here to download .pdf

  152. Barillari G., Gendelman R., Gallo R.C., and Ensoli B. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc. Natl. Acad. Sci. USA 1993, 90: 7941-7945. Click here to download .pdf

  153. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, Gallo RC. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993; 67:277-287. Click here to download .pdf

  154. Rodman TC, To SE, Hashish H, Manchester K. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein. Proc Natl Acad Sci U S A 1993; 90:7719-7723.

  155. Barillari G., Buonaguro L., Fiorelli V., Hoffman J., Michaels F., Gallo R.C., and Ensoli B. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis. J. Immunol. 1992, 149: 3727-3734.Click here to download .pdf

  156. Bohan C.A., Kashanchi F., Ensoli B., Buonaguro L., Boris-Lawrie K.A. and Brady J. Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro. Gene Expr. 1992, 2: 391-407. Click here to download .pdf

  157. Buonaguro L., Barillari G., Chang H.K., Bohan C.A., Kao V., Morgan R., Gallo R.C., and Ensoli B. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J. Virol. 1992, 66: 7159-7167. Click here to download .pdf

  158. Moebius U, Clayton LK, Abraham S, Harrison SC, Reinherz EL. The human immunodeficiency virus gp120 binding site on CD4: delineation by quantitative equilibrium and kinetic binding studies of mutants in conjunction with a high-resolution CD4 atomic structure. J Exp Med 1992; 176:507-517.

  159. Stieneker F, Kreuter J, Lower J. High antibody titres in mice with polymethylmethacrylate nanoparticles as adjuvant for HIV vaccines. AIDS 1991; 5:431-435.

  160. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990; 345:84-86. Click here to download .pdf

  161. Ensoli B. and Gallo RC. Kaposi's sarcoma and AIDS. Nature 1990, 346:801-802. Click here to download .pdf

  162. Lusso P., Di Marzo Veronese F., Ensoli B., Franchini G., Jemma C., DeRocco S.E., Kalyanaraman V.S., and Gallo R.C. Pseudotypes in HIV-1 infected mice. Science 1990, 250: 1152-1154. Click here to download .pdf

  163. Lusso P., Di Marzo Veronese F., Ensoli B., Franchini G., Jemma C., DeRocco S.E., Kalyanaraman V.S., and Gallo R.C. Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses. Science 1990, 247:848-852.Click here to download .pdf

  164. Reiss P, Lange JM, de Ronde A, de Wolf F, Dekker J, Debouck C, Goudsmit J. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. J Med Virol 1990; 30:163-168.

  165. Ensoli B., Nakamura S., Salahuddin S.Z., Biberfeld P., Larsson L., Beaver B., Wong-Staal F., and Gallo R.C. AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 1989, 243: 223-226.Click here to download .pdf

  166. Ensoli B., Lusso P., Schachter F., Josephs S.F., Rappaport J., Negro F., Gallo R.C., and Wong-Staal F. Human herpes virus-6 increases HIV-1 expression in co-infected T cells via nuclear factors binding to the HIV-1 enhancer. EMBO J. 1989, 8:3019-3027. Click here to download .pdf

  167. Lusso P., Ensoli B., Markham P.D., Ablashi D.V., Salahuddin S.Z., Tschachler E., Wong-Staal F., and Gallo R.C. Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV-6. Nature 1989, 337:370-373. Click here to download .pdf

  168. Frankel AD,Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55:1189-1193.

  169. Krone WJ, Debouck C, Epstein LG, Heutink P, Meloen R, Goudsmit J. Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo. J Med Virol 1988; 26:261-270.

  170. Schnittman SM, Lane HC, Roth J, Burrows A, Folks TM, Kehrl JH, Koenig S, Berman P, Fauci AS. Characterization of GP120 binding to CD4 and an assay that measures ability of sera to inhibit this binding. J Immunol 1988; 141:4181-4186.

  171. Fisher AG Ensoli B, Looney D., Rose A, Gallo R.C., Saag MS, Shaw GM, hahn HB, Womg-Staal F. Biologically diverse molecular variants within a single HIV-1 isolate. Nature 1998, vol. 334: 444-447. Click here to download .pdf

  172. Nakamura S., Salahuddin S.Z., Biberfeld P., Ensoli B., Markham P.D., Wong-Staal F., and Gallo RC. Kaposi's sarcoma cells: Long-term culture with growth factor from retrovirus-infected CD4+ T cells. Science 1988, 242: 426-430. Click here to download .pdf

  173. Fisher A., Ensoli B ., Ivanoff L., Chamberlain M., Petteway S., Ratner L., Gallo R.C., and Wong-Staal F. The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 1987, 237: 888-893. Click here to download .pdf

  174. Arya S.K., Beaver B., Jagodzinski L., Ensoli B., Kanki P.J., Albert J., Fenyol E.M., Biberfeld G., Zagury J.F., Laure F., Essex M., Norrby E., Wong-Staal F., and Gallo RC. New human and simian HIV related retroviruses posses functional transactivator (tat) gene. Nature 1987, 328: 548-550.Click here to download .pdf

 
 

 
ISTITUZIONI ITALIANE COINVOLTE
 
   
  CENTRO NAZIONALE AIDS  
       
  ISTITUTO SUPERIORE DI SANITA’  
       
  MINISTERO DELLA SALUTE  
       
  MINISTERO DEGLI AFFARI ESTERI  
       
  OSPEDALE S. GALLICANO  
       
  UNIVERSITA’ DI URBINO  
       
       
   
 
   
      Agenzie governative  
      Pazienti  
      Ricercatori  
      Operatori sanitari  
      Industria  
      Glossario scientifico  
      FAQ (domande frequenti)  
       
  PUBBLICAZIONI SCIENTIFICHE  
       
  LINK UTILI  
       
  CONTATTI  
 

HIV-1 Tat vaccines Italian AIDS vaccines
(C) www.hiv1tat-vaccines.com - Allrights reserved 2007